This HTML5 document contains 55 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
dctermshttp://purl.org/dc/terms/
n6http://localhost/temp/predkladatel/
n18http://linked.opendata.cz/resource/domain/vavai/projekt/
n15http://linked.opendata.cz/resource/domain/vavai/riv/tvurce/
n17http://linked.opendata.cz/resource/domain/vavai/subjekt/
n16http://linked.opendata.cz/ontology/domain/vavai/
shttp://schema.org/
skoshttp://www.w3.org/2004/02/skos/core#
n4http://linked.opendata.cz/ontology/domain/vavai/riv/
n11http://bibframe.org/vocab/
n2http://linked.opendata.cz/resource/domain/vavai/vysledek/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n20http://linked.opendata.cz/resource/domain/vavai/vysledek/RIV%2F61989592%3A15110%2F12%3A33140500%21RIV13-MSM-15110___/
n7http://linked.opendata.cz/ontology/domain/vavai/riv/klicoveSlovo/
n13http://linked.opendata.cz/ontology/domain/vavai/riv/duvernostUdaju/
xsdhhttp://www.w3.org/2001/XMLSchema#
n19http://linked.opendata.cz/ontology/domain/vavai/riv/jazykVysledku/
n8http://linked.opendata.cz/ontology/domain/vavai/riv/aktivita/
n14http://linked.opendata.cz/ontology/domain/vavai/riv/obor/
n9http://linked.opendata.cz/ontology/domain/vavai/riv/druhVysledku/
n12http://reference.data.gov.uk/id/gregorian-year/

Statements

Subject Item
n2:RIV%2F61989592%3A15110%2F12%3A33140500%21RIV13-MSM-15110___
rdf:type
skos:Concept n16:Vysledek
dcterms:description
Introduction: PIK3CA is the oncogene showing the highest frequency of gain-of-function mutations in breast cancer, but the prognostic value of PIK3CA mutation status is controversial. Methods: We investigated the prognostic significance of PIK3CA mutation status in a series of 452 patients with unilateral invasive primary breast cancer and known long-term outcome (median follow-up 10 years). Results: PIK3CA mutations were identified in 151 tumors (33.4%). The frequency of PIK3CA mutations differed markedly according to hormone receptor (estrogen receptor alpha [ER alpha] and progesterone receptor [PR]) and ERBB2 status, ranging from 12.5% in the triple-negative subgroup (ER-/PR-/ERBB2-) to 41.1% in the HR+/ERBB2-subgroup. PIK3CA mutation was associated with significantly longer metastasis-free survival in the overall population (P = 0.0056), and especially in the PR-positive and ERBB2-positive subgroups. In Cox multivariate regression analysis, the prognostic significance of PIK3CA mutation status persisted only in the ERBB2-positive subgroup. Conclusions: This study confirms the high prevalence of PIK3CA mutations in breast cancer. PIK3CA mutation is an emerging tumor marker which might become used in treatment-choosing process. The independent prognostic value of PIK3CA mutation status in ERBB2-positive breast cancer patients should be now confirmed in larger series of patients included in randomized prospective ERBB2-based clinical trials. Introduction: PIK3CA is the oncogene showing the highest frequency of gain-of-function mutations in breast cancer, but the prognostic value of PIK3CA mutation status is controversial. Methods: We investigated the prognostic significance of PIK3CA mutation status in a series of 452 patients with unilateral invasive primary breast cancer and known long-term outcome (median follow-up 10 years). Results: PIK3CA mutations were identified in 151 tumors (33.4%). The frequency of PIK3CA mutations differed markedly according to hormone receptor (estrogen receptor alpha [ER alpha] and progesterone receptor [PR]) and ERBB2 status, ranging from 12.5% in the triple-negative subgroup (ER-/PR-/ERBB2-) to 41.1% in the HR+/ERBB2-subgroup. PIK3CA mutation was associated with significantly longer metastasis-free survival in the overall population (P = 0.0056), and especially in the PR-positive and ERBB2-positive subgroups. In Cox multivariate regression analysis, the prognostic significance of PIK3CA mutation status persisted only in the ERBB2-positive subgroup. Conclusions: This study confirms the high prevalence of PIK3CA mutations in breast cancer. PIK3CA mutation is an emerging tumor marker which might become used in treatment-choosing process. The independent prognostic value of PIK3CA mutation status in ERBB2-positive breast cancer patients should be now confirmed in larger series of patients included in randomized prospective ERBB2-based clinical trials.
dcterms:title
PIK3CA station impact on survival in breast cancer patients and in ERalfa, PR and ERBB2-based subgroups PIK3CA station impact on survival in breast cancer patients and in ERalfa, PR and ERBB2-based subgroups
skos:prefLabel
PIK3CA station impact on survival in breast cancer patients and in ERalfa, PR and ERBB2-based subgroups PIK3CA station impact on survival in breast cancer patients and in ERalfa, PR and ERBB2-based subgroups
skos:notation
RIV/61989592:15110/12:33140500!RIV13-MSM-15110___
n16:predkladatel
n17:orjk%3A15110
n4:aktivita
n8:P
n4:aktivity
P(ED0030/01/01)
n4:cisloPeriodika
1
n4:dodaniDat
n12:2013
n4:domaciTvurceVysledku
n15:5686075
n4:druhVysledku
n9:J
n4:duvernostUdaju
n13:S
n4:entitaPredkladatele
n20:predkladatel
n4:idSjednocenehoVysledku
158707
n4:idVysledku
RIV/61989592:15110/12:33140500
n4:jazykVysledku
n19:eng
n4:klicovaSlova
MODELS; CORRELATE; RESISTANCE; CELLS; CARCINOMA; GENE; IN-SITU; PTEN LOSS; HIGH-FREQUENCY; INHIBITOR NVP-BEZ235
n4:klicoveSlovo
n7:GENE n7:CORRELATE n7:MODELS n7:RESISTANCE n7:HIGH-FREQUENCY n7:INHIBITOR%20NVP-BEZ235 n7:CELLS n7:IN-SITU n7:PTEN%20LOSS n7:CARCINOMA
n4:kodStatuVydavatele
GB - Spojené království Velké Británie a Severního Irska
n4:kontrolniKodProRIV
[C1CAFE30474A]
n4:nazevZdroje
BREAST CANCER RESEARCH
n4:obor
n14:FD
n4:pocetDomacichTvurcuVysledku
1
n4:pocetTvurcuVysledku
9
n4:projekt
n18:ED0030%2F01%2F01
n4:rokUplatneniVysledku
n12:2012
n4:svazekPeriodika
14
n4:tvurceVysledku
Čížková, Magdalena Lidereau, Rosette Driouch, Keltouma Andrieu, Catherine Susini, Aurélie Vacher, Sophie Fourme, Emmanuelle Biéche, Ivan Cizeron-Clairac, Géraldine
n4:wos
000307444100037
s:issn
1465-542X
s:numberOfPages
9
n11:doi
10.1186/bcr3113
n6:organizacniJednotka
15110